Accurate Education – Fibromyalgia: The 4-D Approach to Management

The 4-Domain Approach to Chronic Pain:

Fibromyalgia:

The 4-D Approach to Management

1. Nutraceuticals selected based on the condition of fibromyalgia, hardly an approach that is one size fits all. This represents the conventional approach for the use of nutraceutical in FMS.
2. Selected nutraceuticals introduced based on an individual’s differences in their underlying four domains (4-D) of biopathologies. This 4-D approach is a novel set of protocols presented here.

See:  

Nutraceutical Protocols: 

• Nutraceutical Protocols: Central Post-Stroke Pain (CPSP)
• Nutraceutical Protocols: Chemotherapy-Induced Peripheral Neuropathy (CIPN)
• Nutraceutical Protocols: Chronic Low Back Pain
• Nutraceutical Protocols: Complement Chronic Opioid Therapy
• Nutraceutical Protocols: Complex Regional Pain Syndrome (CRPS)
• Nutraceutical Protocols: Diabetic Peripheral Neuropathy (DPN)
• Nutraceutical Protocols: Fibromyalgia
• Nutraceutical Protocols: Inflammatory Bowel Diseases (IBD)
• Nutraceutical Protocols: Migraine Headaches
• Nutraceutical Protocols: Multiple Sclerosis (MS)-associated pain
• Nutraceutical Protocols: Myofascial Pain Syndrome
• Nutraceutical Protocols: Preventing the Transition From Acute to Chronic Pain After Trauma or Surgery

Key to Links:

• Grey text – handout
• Red text – another page on this website
• Blue text – Journal publication

Definitions and Terms Related to Pain

Fibromyalgia – Part 1

A review of the nutraceuticals recommended for symptoms of fibromyalgia

• The condition of fibromyalgia is not isolated as simply as a pain condition, but rather a syndrome of many different symptoms characteristic to fibromyalgia (see below) with each individual expressing variable severity of these components. Thus, fibromyalgia is often considered to be a syndrome (FMS) rather than a specific disease entity.
• Symptoms: Widespread pain (often described as aching or burning), severe fatigue, sleep problems, cognitive issues (“fibro fog”), headaches, and it is sometimes accompanied by irritable bowel syndrome. It may also include tingling or numbness.
• Causes:
   The exact cause is unknown, but researchers believe it involves central sensitization, where the brain and spinal cord hypersensitively process pain signals. It may be triggered by infections, physical trauma, or emotional stress.

   Pathophysiology Targeted:

• Central and Peripheral Sensitization
• Neuroinflammation
• Mitochondrial Dysfunction
• Oxidative Stress
• Sleep disturbance
• Gut-brain axis dysregulation

   Evidence Summary:

Fibromyalgia represents a nociplastic pain condition where opioids are generally less effective.[10] Nutraceutical interventions show promise, with evidence supporting magnesium, CoQ10, vitamin D, and omega-3 supplementation.[11][12] Lower serum magnesium levels correlate with poorer sleep quality, hi gher pain severity, and greater functional impairment in FM patients.[13]

Nutraceuticals suggested for managing the symptos of fibromyalgia

Magnesium + Tryptophan Mediterranean Diet: A 16-week RCT showed that a Mediterranean diet enriched with tryptophan (60 mg) and magnesium (60 mg) significantly reduced trait anxiety, mood disturbance, eating disorders, and body image dissatisfaction in FM patients.[15]

   Protocol Notes:

• Emphasize sleep optimization with melatonin as cornerstone
• Magnesium citrate (L Threonate smay be preferred) 300 mg daily showed efficacy on tender points and FIQ when combined with amitriptyline[14]
• Consider low-saturated fat, low-added sugar dietary pattern to reduce neuroinflammation via gut-brain axis[18]
• PEA effective for nociplastic pain type specifically[6]
• Avoid high-dose opioids; guidelines recommend against opioids for FM[10]
• Address comorbid conditions: anxiety, depression, sleep disorders

Key Supplements:

• Magnesium: Helps reduce tender points and muscle pain. Take 300–400 mg daily. The citrate form works well but may cause loose stools initially.
• Melatonin: Improves sleep quality, which is critical for fibromyalgia. Take 5–10 mg at bedtime.
• CoQ10: Supports energy production in your cells. Take 300 mg daily.
• PEA: Reduces the oversensitivity of your pain system. Take 600 mg twice daily initially.

What to Expect: Sleep often improves first (within 1–2 weeks), followed by gradual pain reduction over 4–8 weeks.

Fibromyalgia – Part 2

The 4 Domain (4-D) Approach to the Management of Fibromyalgia (FMS)

The 4-D Approach  is a different conceptual framework wuth a core insight:

“The severity of the pain experience is determined not just by the pain condition itself, but by how each individual’s unique profile across 4 domains (systemic inflammation, neuroinflammation, oxidative stress, mitochondrial dysfunction) modulates their pain processing.”

This concept represents a shift from condition-centric to patient-centric nutraceutical management. The condition-specific approach presented above uses stacking architectures of nutraceuticals (starting with one, then adding another based on symptomatic response only). What follows here is a framework for how individual 4-D domain profiling can modify those condition-specific protocols.

This reconciliation of this shift is supported by emerging evidence. A landmark biomarker study of 17,834 chronic pain patients found that 77% exhibited at least one abnormal biomarker, with the most common being elevated quinolinic acid (29%, neuroinflammation marker), elevated pyroglutamate (19%, glutathione depletion/oxidative stress), elevated xanthurenic acid (17%, B6 insufficiency), and elevated methylmalonic acid (10%, B12 deficiency).[1]

Critically, these abnormalities varied substantially across individuals — confirming that chronic pain patients are not biochemically homogeneous and that a one-size-fits-all approach misses targetable individual variation. Similarly, a study of chronic osteoarthritis patients demonstrated that elevated oxidative stress (F2-isoprostanes) was specifically associated with the “dysfunctional chronic pain phenotype” — characterized by greater pain intensity, more widespread pain, and higher catastrophizing — rather than with the diagnosis itself.[2]

—

The Reconciliation Framework for FMS:

Condition-Specific Architecture FMS + Individual 4D Modifiers

The condition-specific approach to the management of fibromyalgia establish the stacking architecture — which nutraceuticals to use, in what sequence, at what doses. The 4-D individual profile then acts as a modifier layer that adjusts priorities, sequencing, and emphasis within that architecture. The condition determines the blueprint; the individual’s 4-D profile determines the execution.

—

FIBROMYALGIA: 4-D Domain-Modified Protocol

The FMS condition-centric approach establishes three sequential phases

• Phase A: Mitochondrial Rescue & Oxidative Stress Reduction
• Phase B: Neuroinflammation Suppression
• Phase C: Descending Modulation & E/I Rebalancing

The individual’s 4D profile modifies this architecture in the following ways:

Profile 1: Neuroinflammation-Dominant FMS

Clinical indicators: Prominent allodynia and hyperalgesia out of proportion to tender point count; severe cognitive dysfunction (“fibro fog”); high FIQR cognitive subscale; elevated hs-CRP and/or IL-6/IL-8; poor response to gabapentinoids (which primarily target ion channels, not glial activation); history of autoimmune comorbidities or chronic infections; PET imaging showing elevated TSPO (where available).[3][4]

   Modification strategy:

1. Elevate Phase B to first priority — begin with neuroinflammation suppression before mitochondrial rescue
2. Accelerate PEA + ALC introduction — move from Phase B to immediately after Tier 2, as the RCT evidence for PEA + ALC in FMS specifically targets neuroinflammatory mechanisms (glial modulation, mast cell stabilization)
3. Prioritize Boswellia — the FMS preclinical model data showing reduction of astrocyte/microglial activation in dorsal horn and prefrontal cortex, with restoration of Nrf2/HO-1/NQO1 and neurotransmitter levels, makes Boswellia particularly high-yield in this profile[5]
4. Add sulforaphane early — Nrf2 dysfunction is specifically implicated in FMS pathogenesis, and sulforaphane’s anti-neuroinflammatory effects (↓CD11b/c, ↓NOS2) complement PEA’s glial modulation
5. Melatonin at higher dose (5 mg) — the FMS preclinical model demonstrated melatonin reduces microglial activation via SIRT1/PGC-1α and reduces NMDAR2B in spinal cord[6]
6. Phase A agents (CoQ10, ALA, NAC, D-Ribose, NR) become secondary additions after neuroinflammation is being addressed

Co-medication synergies:

In patients on duloxetine + pregabalin, the PEA + ALC combination has direct RCT evidence as add-on therapy showing significant improvements in WPI, FIQR, and FASmod. Duloxetine’s serotonergic/noradrenergic effects on descending inhibition are mechanistically complementary to melatonin’s MT2-mediated PAG activation and PEA’s endocannabinoid enhancement — these target different nodes of the descending inhibitory circuit.[7][8]

Profile 2: Oxidative Stress-Dominant FMS

Clinical indicators: Severe fatigue disproportionate to pain severity; high FIQR fatigue subscale; exercise intolerance with post-exertional malaise; elevated MDA or F2-isoprostanes (where available); low CoQ10 levels; elevated pyroglutamate (indicating glutathione depletion); medication hypersensitivity (suggesting impaired detoxification capacity); comorbid chemical sensitivity.[9][1][2]

   Modification strategy:

• Phase A remains first priority — the mitochondrial rescue and oxidative stress reduction phase directly addresses the dominant domain
• Prioritize NAC — as the rate-limiting cysteine donor for glutathione synthesis, NAC directly addresses the glutathione depletion (elevated pyroglutamate) that is the second most common biomarker abnormality in chronic pain patients (19%)[1]
• CoQ10 becomes highest-priority Phase A agent — the FMS-specific RCT demonstrated that CoQ10 300 mg/day significantly reduced FIQ, pain VAS, fatigue, and tender points while increasing AMPK and mitochondrial biogenesis gene expression
• Add sulforaphane early — as the most potent natural Nrf2 inducer, sulforaphane activates the master antioxidant response pathway; Nrf2 dysfunction is specifically implicated in FMS pathogenesis[10]
• D-Ribose and NR receive higher priority — the pilot study showing 45% increase in energy VAS and 66% significant improvement in FM/CFS patients directly addresses the energy deficit phenotype[11]
• Phase B agents (PEA, ALC, Boswellia) become secondary additions

Co-medication synergies:

In patients on gabapentin/pregabalin, isobolographic analysis in diabetic neuropathy models demonstrates that CoQ10 and ALA produce synergistic interactions with gabapentinoids — with up to 30-fold dose reductions of both drugs when combined.[12] This suggests that oxidative stress-dominant patients on gabapentinoids may derive particular benefit from early CoQ10 + ALA introduction, potentially allowing gabapentinoid dose reduction.

Profile 3: Mitochondrial Dysfunction-Dominant FMS

Clinical indicators: Profound fatigue as the primary complaint (often exceeding pain severity); severe exercise intolerance with delayed recovery; poor muscle endurance; comorbid chronic fatigue syndrome/ME; low CoQ10 levels; elevated lactate; poor response to anti-inflammatory agents (suggesting the pain driver is metabolic rather than inflammatory).[9][10][13]

   Modification strategy:

• Phase A is the primary therapeutic target — maximize mitochondrial rescue
• Full mitochondrial stack deployed early: CoQ10 (300 mg) + ALA (600 mg) + D-Ribose (15 g/day) + NR (250–500 mg) + NAC (1,200 mg) — the combined supplementation of CoQ10/vitamin D/ALA/magnesium/tryptophan showed FM pain reduction at 1 month[9]
• Benfotiamine receives emphasis within the B-complex (Tier 1) — as a mitochondrial ETC cofactor (pyruvate dehydrogenase), benfotiamine directly supports the rate-limiting step of mitochondrial energy production
• Resveratrol elevated in priority — SIRT1 activation drives mitochondrial biogenesis via PGC-1α, directly addressing the biogenesis deficit
• Phase B and C agents are added only after metabolic restoration shows clinical response (FIQR fatigue subscale improvement)

Co-medication synergies:

Patients on chronic opioids may have compounded mitochondrial dysfunction, as opioids themselves impair mitochondrial function. Agmatine (Tier 2) becomes particularly important in this profile — not only for NMDAR antagonism but for its opioid-potentiating effects that may allow dose reduction, thereby reducing opioid-mediated mitochondrial burden.[14][15]

Profile 4: Systemic Inflammation-Dominant FMS

Clinical indicators: Elevated hs-CRP (>3 mg/L); elevated ESR; high omega-6:omega-3 ratio; comorbid metabolic syndrome, obesity, or autoimmune conditions; pain that worsens with dietary inflammatory triggers; elevated IL-6, TNF-α; joint stiffness and swelling beyond typical FMS presentation.[3][16]

   Modification strategy:

• Tier 1 omega-3 receives maximum emphasis — the meta-analysis of 41 RCTs (n=3,759) demonstrated moderate pain reduction (SMD -0.55) with effect improving over time (SMD -0.83 at 6 months)
• Curcumin elevated to Phase A (moved from Phase C) — strong NF-κB and COX-2 inhibition directly addresses systemic inflammatory burden
• Boswellia elevated to Phase A — the OA RCT demonstrated significant reductions in IL-6, TNF-α, and hs-CRP with 300 mg Boswellia × 90 days; combined curcumin + boswellia provides dual COX-2 + 5-LOX pathway coverage
• Quercetin elevated in priority — the RCT in rheumatoid arthritis demonstrated significant reduction in inflammatory factors and clinical symptoms
• Dietary intervention emphasized — anti-inflammatory dietary patterns (low-FODMAP, Mediterranean) may be as important as supplementation in this profile[17][18]

Co-medication synergies:

In patients on NSAIDs, curcumin and boswellia provide complementary anti-inflammatory mechanisms (NF-κB/COX-2 and 5-LOX respectively) that may allow NSAID dose reduction, reducing GI and cardiovascular risk. Omega-3 fatty acids’ resolvin/protectin production provides a pro-resolution pathway distinct from the anti-inflammatory pathways targeted by NSAIDs.[19]

—

FMS 4-D Decision Matrix

The following table summarizes how the dominant domain modifies nutraceutical prioritization within the FMS protocol:

[5][6][11][9][10][1][12]

★★★ = First priority / Elevate in sequence;

★★ = Standard position per handout protocol;

★ = Lower priority / defer

—

Integrating Co-Medication Synergy Into the 4-D Framework

A critical dimension of the 4-D approach is leveraging synergies between nutraceuticals and co-administered medications. The principle of combining agents with different mechanisms or sites of action to attack multiple targets simultaneously is well-established in combination pharmacotherapy for chronic pain.[8] The nutraceutical stack extends this principle by adding non-sedating, peripherally and centrally acting agents that do not compound the CNS-depressant side effects common to opioid-gabapentinoid-antidepressant combinations.[28][8]

   Key synergy pairs relevant to FMS:

• Agmatine + opioids: GluN2B NMDAR antagonism potentiates opioid analgesia while preventing opioid-induced hyperalgesia and behavioral sensitization[14][15]
• PEA + ALC + duloxetine + pregabalin: Direct RCT evidence of synergistic benefit in FMS
• CoQ10/ALA + gabapentinoids: Isobolographic synergy demonstrated in neuropathic pain models[12]
• Melatonin + antidepressants: RCT evidence that melatonin + fluoxetine produces superior FMS outcomes to either alone
• Sulforaphane + opioids: Preclinical evidence that sulforaphane increases mu-opioid receptor expression and enhances morphine analgesia[29]

—

Conclusion

This framework establishes the principle that the FMS condition-centric approachl serves as the architectural template, while the individual’s 4-D profile determines the execution priorities. The same nutraceuticals are used, but their sequencing, emphasis, and pairing with co-medications shift based on which domain(s) are most prominent in the individual patient.

References

1. An Analysis of Biomarkers in Patients With Chronic Pain. Gunn J, Hill MM, Cotten BM, Deer TR. Pain Physician. 2020;23(1):E41-E49.
2. Oxidative Stress Is Associated With Characteristic Features of the Dysfunctional Chronic Pain Phenotype. Bruehl S, Milne G, Schildcrout J, et al. Pain. 2022;163(4):786-794. doi:10.1097/j.pain.0000000000002429.
3. Potential Role of Blood Biomarkers in Patients With Fibromyalgia: A Systematic Review With Meta-Analysis. Kumbhare D, Hassan S, Diep D, et al. Pain. 2022;163(7):1232-1253. doi:10.1097/j.pain.0000000000002510.
4. “Neuroinflammation”: Does It Have a Role in Chronic Pain? Evidence From Human Imaging. Loggia ML. Pain. 2024;165(11S):S58-S67. doi:10.1097/j.pain.0000000000003342.
5. Effects of Vitamin D on Patients With Fibromyalgia Syndrome: A Randomized Placebo-Controlled Trial. Wepner F, Scheuer R, Schuetz-Wieser B, et al. Pain. 2014;155(2):261-268. doi:10.1016/j.pain.2013.10.002.
6. Response to Vitamin B12 and Folic Acid in Myalgic Encephalomyelitis and Fibromyalgia. Regland B, Forsmark S, Halaouate L, et al. PloS One. 2015;10(4):e0124648. doi:10.1371/journal.pone.0124648.
7. Antidepressants and Gabapentinoids in Neuropathic Pain: Mechanistic Insights. Kremer M, Salvat E, Muller A, Yalcin I, Barrot M. Neuroscience. 2016;338:183-206. doi:10.1016/j.neuroscience.2016.06.057.
8. Combination Pharmacotherapy for Management of Chronic Pain: From Bench to Bedside. Gilron I, Jensen TS, Dickenson AH. The Lancet. Neurology. 2013;12(11):1084-95. doi:10.1016/S1474-4422(13)70193-5.
9. Oxidative Stress in Fibromyalgia: From Pathology to Treatment. Assavarittirong C, Samborski W, Grygiel-Górniak B. Oxidative Medicine and Cellular Longevity. 2022;2022:1582432. doi:10.1155/2022/1582432.
10. Redox Reactions in Chronic Pain: Mechanisms and Relevance in Fibromyalgia. Ho T, Ryan M, Holle J. Frontiers in Pain Research (Lausanne, Switzerland). 2025;6:1593908. doi:10.3389/fpain.2025.1593908.
11. Ultramicronized Palmitoylethanolamide (Um-Pea) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients. Schweiger V, Martini A, Bellamoli P, et al. CNS & Neurological Disorders Drug Targets. 2019;18(4):326-333. doi:10.2174/1871527318666190227205359.
12. Levetiracetam Synergizes With Gabapentin, Pregabalin, Duloxetine and Selected Antioxidants in a Mouse Diabetic Painful Neuropathy Model. Stepanović-Petrović R, Micov A, Tomić M, Pecikoza U. Psychopharmacology. 2017;234(11):1781-1794. doi:10.1007/s00213-017-4583-z.
13. Neuronutritional Approach to Fibromyalgia Management: A Narrative Review. Badaeva A, Danilov A, Kosareva A, et al. Pain and Therapy. 2024;13(5):1047-1061. doi:10.1007/s40122-024-00641-2.
14. Determination of Α(2)-Adrenoceptor and Imidazoline Receptor Involvement in Augmentation of Morphine and Oxycodone Analgesia by Agmatine and BMS182874. Bhalla S, Rapolaviciute V, Gulati A. European Journal of Pharmacology. 2011;651(1-3):109-21. doi:10.1016/j.ejphar.2010.10.090.
15. Agmatine Ameliorates Morphine-Induced Behavioral Sensitization Through Blood-Brain Barrier Protection and Anti-Neuroinflammatory Effects in the Nucleus Accumbens. Ma H, Tian W, Xiao J, et al. Psychopharmacology. 2025;:10.1007/s00213-025-06944-2. doi:10.1007/s00213-025-06944-2.
16. Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?. Menzel A, Samouda H, Dohet F, et al. Antioxidants (Basel, Switzerland). 2021;10(3):414. doi:10.3390/antiox10030414.
17. Review of Nutritional Approaches to Fibromyalgia. Kadayifci FZ, Bradley MJ, Onat AM, Shi HN, Zheng S. Nutrition Reviews. 2022;80(12):2260-2274. doi:10.1093/nutrit/nuac036.
18. Nociplastic Pain: Towards an Understanding of Prevalent Pain Conditions. Fitzcharles MA, Cohen SP, Clauw DJ, et al. Lancet (London, England). 2021;397(10289):2098-2110. doi:10.1016/S0140-6736(21)00392-5.
19. Insights on Nutrients as Analgesics in Chronic Pain. Bjørklund G, Chirumbolo S, Dadar M, et al. Current Medicinal Chemistry. 2020;27(37):6407-6423. doi:10.2174/0929867326666190712172015.
20. Can Coenzyme Q10 Improve Clinical and Molecular Parameters in Fibromyalgia?. Cordero MD, Alcocer-Gómez E, de Miguel M, et al. Antioxidants & Redox Signaling. 2013;19(12):1356-61. doi:10.1089/ars.2013.5260.
21. Retrospective Evaluation of L-Acetyl Carnitine and Palmitoylethanolamide as Add-on Therapy in Patients With Fibromyalgia and Small Fiber Neuropathy. Bentivenga C, Cicero AFG, Fogacci F, et al. Pharmaceutics. 2025;17(8):1004. doi:10.3390/pharmaceutics17081004.
22. Palmitoylethanolamide and Acetyl-L-Carnitine Act Synergistically With Duloxetine and Pregabalin in Fibromyalgia: Results of a Randomised Controlled Study. Salaffi F, Farah S, Sarzi-Puttini P, Di Carlo M. Clinical and Experimental Rheumatology. 2023;41(6):1323-1331. doi:10.55563/clinexprheumatol/pmdzcq.
23. Melatonin Mitigates Central Sensitization and Nociplastic Pain in Spinal Cord and Dorsal Root Ganglia of FM Rat Model: Modulation of SIRT1/PGC-1α/MAPK/NF-κB Signaling. Osama J, El-Gazar AA, Ragab GM, El-Sayed NS, Kamel AS. Journal of Neuroimmune Pharmacology : The Official Journal of the Society on NeuroImmune Pharmacology. 2026;21(1):12. doi:10.1007/s11481-025-10274-7.
24. Psychological Outcomes and Quality of Life of Fibromyalgia Patients With Vitamin D Supplementation-a Meta-Analysis. Yang CC, Tsai ST, Ting B, et al. Journal of Clinical Medicine. 2023;12(7):2750. doi:10.3390/jcm12072750.
25. Micronutrients and Chronic Pain: A Cross-Sectional Analysis. Goon M, Schmidt N, Berwal D, et al. Pain Practice : The Official Journal of World Institute of Pain. 2025;25(5):e70053. doi:10.1111/papr.70053.
26. Integrative neuromuscular medicine: Neuropathy and neuropathic pain: Consider the alternatives. Rowin J. Muscle & Nerve. 2019;60(2):124-136. doi:10.1002/mus.26510.
27. Role of Vitamin D Supplementation in the Management of Musculoskeletal Diseases: Update From an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Working Group. Chevalley T, Brandi ML, Cashman KD, et al. Aging Clinical and Experimental Research. 2022;34(11):2603-2623. doi:10.1007/s40520-022-02279-6.
28. Combination Pharmacotherapy for the Treatment of Neuropathic Pain in Adults: Systematic Review and Meta-Analysis. Balanaser M, Carley M, Baron R, et al. Pain. 2023;164(2):230-251. doi:10.1097/j.pain.0000000000002688.
29. MED1/BDNF/TrkB Pathway Is Involved in Thalamic Hemorrhage-Induced Pain and Depression by Regulating Microglia. Infantino R, Schiano C, Luongo L, et al. Neurobiology of Disease. 2022;164:105611. doi:10.1016/j.nbd.2022.105611.

References for Fibromyalgia – Part 1

1. A Systematic Guideline by the ASPN Workgroup on the Evidence, Education, and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET. Sayed D, Deer TR, Hagedorn JM, et al. Journal of Pain Research. 2024;17:1461-1501. doi:10.2147/JPR.S451006.
2. The Role of Diet and Non-Pharmacologic Supplements in the Treatment of Chronic Neuropathic Pain: A Systematic Review. Frediani JK, Lal AA, Kim E, et al. Pain Practice : The Official Journal of World Institute of Pain. 2024;24(1):186-210. doi:10.1111/papr.13291.
3. The Neuroprotective Effects of Micronized PEA (PEA-m) Formulation on Diabetic Peripheral Neuropathy in Mice. Impellizzeri D, Peritore AF, Cordaro M, et al. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2019;33(10):11364-11380. doi:10.1096/fj.201900538R.
4. Pathogenetic Treatments for Diabetic Peripheral Neuropathy. Ziegler D. Diabetes Research and Clinical Practice. 2023;206 Suppl 1:110764. doi:10.1016/j.diabres.2023.110764.
5. Biomarkers of Response to Alpha-Lipoic Acid ± palmitoiletanolamide Treatment in Patients With Diabetes and Symptoms of Peripheral Neuropathy. Pieralice S, Vari R, Minutolo A, et al. Endocrine. 2019;66(2):178-184. doi:10.1007/s12020-019-01917-w.
6. Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
7. Nutraceutical Approach to Peripheral Neuropathies: Evidence From Clinical Trials. Mostacci B, Liguori R, Cicero AF. Current Drug Metabolism. 2018;19(5):460-468. doi:10.2174/1389200218666171031145419.
8. Dietary and Nutritional Supplementation for Painful Diabetic Neuropathy: A Narrative Review. Apergi K, Papanas N. Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association. 2023;131(12):646-655. doi:10.1055/a-2188-1745.
9. Diabetic Peripheral Neuropathy: Prevention and Treatment. Bragg S, Marrison ST, Haley S. American Family Physician. 2024;109(3):226-232.
10. Nociplastic Pain: Towards an Understanding of Prevalent Pain Conditions. Fitzcharles MA, Cohen SP, Clauw DJ, et al. Lancet (London, England). 2021;397(10289):2098-2110. doi:10.1016/S0140-6736(21)00392-5.
11. Review of Nutritional Approaches to Fibromyalgia. Kadayifci FZ, Bradley MJ, Onat AM, Shi HN, Zheng S. Nutrition Reviews. 2022;80(12):2260-2274. doi:10.1093/nutrit/nuac036.
12. Fibromyalgia and Nutrition: Therapeutic Possibilities?. Bjørklund G, Dadar M, Chirumbolo S, Aaseth J. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2018;103:531-538. doi:10.1016/j.biopha.2018.04.056.
13. Serum Magnesium Levels and Their Association With Sleep Quality and Disease Severity in Fibromyalgia Syndrome: An Observational Cross-Sectional Study. Alisik T, Reis Altan YC, Olkay SG, Sahingoz Bakirci E. Medicine. 2025;104(29):e43446. doi:10.1097/MD.0000000000043446.
14. Is Magnesium Citrate Treatment Effective on Pain, Clinical Parameters and Functional Status in Patients With Fibromyalgia?. Bagis S, Karabiber M, As I, et al. Rheumatology International. 2013;33(1):167-72. doi:10.1007/s00296-011-2334-8.
15. Psychological and Sleep Effects of Tryptophan and Magnesium-Enriched Mediterranean Diet in Women With Fibromyalgia. Martínez-Rodríguez A, Rubio-Arias JÁ, Ramos-Campo DJ, et al. International Journal of Environmental Research and Public Health. 2020;17(7):E2227. doi:10.3390/ijerph17072227.
16. Targeted Treatment of Age-Related Fibromyalgia With Supplemental Coenzyme Q10. Hargreaves IP, Mantle D. Advances in Experimental Medicine and Biology. 2021;1286:77-85. doi:10.1007/978-3-030-55035-6_5.
17. Bioactive Compounds for Fibromyalgia-Like Symptoms: A Narrative Review and Future Perspectives. Shen CL, Schuck A, Tompkins C, Dunn DM, Neugebauer V. International Journal of Environmental Research and Public Health. 2022;19(7):4148. doi:10.3390/ijerph19074148.
18. Nutritional Intervention in Chronic Pain: An Innovative Way of Targeting Central Nervous System Sensitization?. Nijs J, Tumkaya Yilmaz S, Elma Ö, et al. Expert Opinion on Therapeutic Targets. 2020;24(8):793-803. doi:10.1080/14728222.2020.1784142.
19. Is the Gut Microbiome of Importance in Fibromyalgia? A Critical Review of Emerging Evidence. Shtrozberg S, Bazzichi L, Sarzi-Puttini P, Aloush V, Ablin JN. Clinical and Experimental Rheumatology. 2025;43(6):990-998. doi:10.55563/clinexprheumatol/pmajsv.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

.